Prolonged oral etoposide in small cell lung cancer

This publication has 11 references indexed in Scilit:

• Report of the Cancer Therapy Evaluation Program Monitoring Plan for Secondary Acute Myeloid Leukemia Following Treatment With Epipodophyllotoxins
  JNCI Journal of the National Cancer Institute, 1993
• Bioavailability of low-dose oral etoposide.
  Journal of Clinical Oncology, 1993
• Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma
  European Journal of Cancer and Clinical Oncology, 1991
• Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia
  New England Journal of Medicine, 1991
• Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours
  The Lancet, 1991
• Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.
  Journal of Clinical Oncology, 1990
• Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
  Journal of Clinical Oncology, 1990
• A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
  Journal of Clinical Oncology, 1989
• A phase II study of oral etoposide in elderly patients with small cell lung cancer.
  Thorax, 1989
• The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung
  Cancer Chemotherapy and Pharmacology, 1987